Since antiapoptotic genes belong to the target genes of NF-κB, this implies a potential survival advantage for metastasizing prostate cancer cells caused by the treatment leading to the notion that a combined anti-AR/anti-NF-κB treatment might outperform the standard antiandrogen treatment. The gene discussed is AR; the disease is prostate cancer.